Aker (OB:AKER) Sees Record Superba Demand, Is The Premium Already Priced In?

Recent news around Aker (OB:AKER) centers on Aker BioMarine, where record sales for Superba krill oil, a major new customer contract, and an active review of the Human Health Ingredients segment have drawn fresh attention to the stock.

See our latest analysis for Aker.

The recent momentum in Aker’s Human Health Ingredients activities sits alongside a strong share price run, with a 90 day share price return of 14.63% and a year to date share price return of 56.87%. The 1 year total shareholder return of 93.48% underlines how sentiment has shifted over a longer period.

If Aker’s recent move has you rethinking where the next opportunity could come from, this can be a good moment to broaden your search with 105 top founder-led companies

Aker’s mix of industrial holdings and krill driven growth has clearly caught the market’s eye, but after such a strong run, is the stock still offering solid value, or are investors now paying up for quality?

Price to earnings for Aker: is the premium justified?

Aker currently trades on a P/E of 22.3x, which sits above both the European Industrials industry average of 17.8x and the estimated fair P/E of 17.1x. This means the market is paying a clear premium relative to these benchmarks at the last close of NOK1,222.

The P/E ratio compares Aker's share price to its reported earnings per share. A higher figure typically means investors are willing to pay more for each unit of current earnings, often when they see a more resilient profit profile, higher quality assets or a better mix of businesses than the sector as a whole.

Relative to peers, Aker's P/E of 22.3x is described as expensive against the wider European Industrials industry at 17.8x. It also sits above the estimated fair P/E of 17.1x that our fair ratio work suggests the market could eventually lean toward, which points to investors already pricing in stronger prospects or higher perceived quality than the headline earnings history alone would indicate.

Explore the SWS fair ratio for Aker

Result: Price-to-earnings of 22.3x (OVERVALUED).

However, Aker’s P/E premium could be challenged if its diverse holdings face weaker earnings, or if sentiment toward krill-driven and energy-related assets cools.

Find out about the key risks to this Aker narrative.

Another view on Aker using our DCF model

While Aker looks expensive on a P/E of 22.3x, the SWS DCF model also points to the shares trading above an estimated value, with the current price of NOK1,222 compared with a DCF value of NOK933.82. That gap raises a simple question: how much optimism is already in the price?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Aker for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 212 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and concern around Aker leaves you undecided, take a closer look at the data now and shape your own view with 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Aker?

Do not stop your research with Aker. Some of the most interesting opportunities often sit just outside your current watchlist, waiting for a closer look.

• Target resilient balance sheets and robust fundamentals by running the solid balance sheet and fundamentals stocks screener (420 results).
• Hunt for quality companies that the market might be overlooking with the screener containing 500 high quality undiscovered gems.
• Strengthen your income focus by scanning for potential high yield opportunities using the 471 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com